share_log

Lexicon Pharmaceuticals to Participate in December Investor Conferences

Lexicon Pharmaceuticals to Participate in December Investor Conferences

萊斯康製藥將在十二月參加投資者會議
GlobeNewswire ·  2024/11/26 05:15

THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer and director, will present at two upcoming investor conferences in December.

德克薩斯州伍德蘭茲,2024年11月25日(GLOBE NEWSWIRE)——Lexicon Pharmicals, Inc.(納斯達克股票代碼:LXRX)今天宣佈,包括Lexicon首席執行官兼董事邁克·埃克斯頓在內的公司管理層將出席即將於12月舉行的兩次投資者會議。

  • Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET
  • 7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ET
  • 派珀·桑德勒第 36 屆年度醫療保健會議:美國東部時間 2024 年 12 月 3 日星期二上午 8:00 的演講
  • 第七屆年度 Evercore HealthConx 會議:美國東部時間 2024 年 12 月 5 日星期四下午 12:30 的演講

Simultaneous webcasts will be available in the "Events" section of the Lexicon website at , and a recording of the webcasts will be available for two weeks following the original on-demand date.

Lexicon網站的 「活動」 部分將提供同步網絡直播,網絡廣播的錄像將在最初的點播日期之後的兩週內提供。

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000 program, Lexicon's unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit .

關於 Lexicon 製藥
Lexicon 是一家生物製藥公司,其使命是開創改變患者生活的藥物。通過Lexicon獨特的基因組學靶點發現平台Genome5000計劃,Lexicon科學家研究了近5,000個基因的作用和功能,並確定了100多個在一系列疾病中具有巨大治療潛力的蛋白質靶標。通過精確靶向這些蛋白,Lexicon開創了安全有效地治療疾病的創新藥物的發現和開發。Lexicon擁有一系列有前途的候選藥物,用於神經病理性疼痛、肥厚型心肌病(HCM)、肥胖、新陳代謝和其他適應症的發現、臨床和臨床前開發。如需更多信息,請訪問。

Investors and Media
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

投資者和媒體
麗莎·德弗朗西斯科
Lexicon Pharmicals, Inc
lexinvest@lexpharma.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論